Skip to main content

Table 5 Multivariate-adjusteda stratified analyses of overall mortality according to tertiles of serum 25(OH)D

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

   Serum 25(OH)D
   Continuous Categorical  
   per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L  
Variable Total no. HR 95%CI P trend b HR 95%CI HR 95%CI   P interaction c
BMI, kg/m2d           0.74
   < 26 382 1.05 0.66 to 1.44 0.81 0.64 0.08 to 5.00 0.02 0.00 to 2.06 Referent  
   ≥ 26 393 1.15 0.94 to 1.36 0.20 2.57 0.88 to 7.54 0.60 0.19 to 1.92 Referent  
Leisure time physical activity, MET-h/wk           0.49
   < 37 631 1.04 0.92 to 1.17 0.50 1.19 0.62 to 2.29 0.63 0.30 to 1.32 Referent  
   ≥ 37 629 1.19 1.03 to 1.35 0.03 1.90 0.85 to 4.24 0.57 0.22 to 1.48 Referent  
HRT use           0.40
   Never, past 746 1.13 1.01 to 1.25 0.04 1.89 1.09 to 3.26 0.61 0.31 to 1.19 Referent  
   Current 506 1.03 0.86 to 1.21 0.73 0.89 0.26 to 3.05 1.17 0.46 to 2.98 Referent  
ER status           0.78
   ER+ 903 1.08 0.97 to 1.19 0.17 1.70 0.95 to 3.05 0.72 0.39 to 1.35 Referent  
   ER- 276 1.09 0.84 to 1.35 0.50 1.48 0.38 to 5.76 0.81 0.21 to 3.09 Referent  
  1. 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy.
  2. a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection.
  3. b Calculated by using serum 25(OH)D as a continuous variable.
  4. c Calculated by entering in the model the cross-product of 25(OH)D as a continuous variable with the covariate as a binary variable. Cutpoints for BMI and leisure time physical activity were based on median values.
  5. d Participants with blood collection after start of chemotherapy and with BMI obtained more than one month before/after blood collection were excluded from this analysis stratified by BMI.